Oral Fingolimod reduces MS disease activity - larger, Phase 3 study underway
In a Phase 2 controlled clinical trial involving 255 people with active, relapsing multiple sclerosis, oral fingolimod significantly reduced signs of inflammation on MRI scans.
To read more, please click on the link below.
Source: US National MS Society Weblink: click here
